Bruton’s tyrosine kinase (BTK) inhibitors are one of the most mature and most fiercely competitive tracks in the B-cell malignancy treatment field. The first-generation BTK inhibitor ibrutinib, because of limited kinase selectivity, has off-target effects leading to atrial fibrillation, bleeding and other side effects; while second-generation drugs represented by zanubrutinib and acalabrutinib, by improving selectivity for BTK and reducing off-target toxicity, have optimized safety. However, whether first- or second-generation, they all rely on the covalent binding mechanism; once BTK undergoes a C481 mutation, the drug can no longer form a covalent bond, which gave rise to Eli Lilly’s third-generation non-covalent BTK inhibitor pirtobrutinib. In this arms race that has lasted over a decade, Lupeng Pharmaceuticals has offered a disruptive answer: break the binary choice between covalent and non-covalent, and put the dual mechanisms into the same molecule.
On June 3, 2026, lobrutinib tablets (Lubujia, LP-168), a Category 1 innovative drug independently developed by Lupeng Pharmaceuticals, officially received marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have previously received at least two systemic therapies (including BTK inhibitors), becoming the world’s first and currently only covalent-and-non-covalent fourth-generation BTK inhibitor.
On the occasion of the 2026 China Pharmaceutical Innovation Conference (CPIC), “Yao Chuangxin”(Pharma Innovation) interviewed Dr. Yi Chen, Lupeng’s co-founder and chief scientist. In the interview, Dr. Chen began with the molecular design principles of lobrutinib, talked about how the company made up its mind to conduct a global head-to-head phase 3 clinical trial, and also discussed the layout of the company’s entire pipeline in terms of combination therapy and indication expansion.
Dual covalent and non-covalent mechanism of action: locking the target while simultaneously inhibiting mutations
BTK inhibitors have gone through multiple rounds of iteration to date. First- and second-generation BTK inhibitors bind the C481 residue of the BTK kinase domain through an irreversible covalent bond — once bound, it is extremely hard to disengage, so efficacy is durable and activity is strong. Yet this is also their Achilles’ heel: once BTK develops a mutation such as C481S, the covalent bond can no longer be formed, leading to resistance. To overcome this, Eli Lilly’s third-generation BTK inhibitor pirtobrutinib shifted to a non-covalent binding mode, replacing “welding”with “hugging” to inhibit the mutated target, but remains weak against other BTK mutations (such as T474I, L528W), and the clinical demand for new solutions remains urgent.
Covalent and non-covalent have always been regarded, in terms of chemical mechanism, as a “single-choice question” — you must pick one or the other. Dr. Chen said: “Before us, covalent and non-covalent were absolutely opposed — you could only pick one of two.” What lobrutinib set out to do is precisely to break this multiple-choice question, and merge the two mechanisms into a single molecule.
Dr. Chen explained the underlying logic of this design: at the level of a single BTK molecule, a drug molecule can indeed bind the target through only one of the two modes — covalent or non-covalent — and this cannot be changed. However, within a cancer patient there are typically thousands upon thousands of cancer cells, with some BTK still wild-type and others having already acquired a C481 mutation. “If lobrutinib enters a wild-type cancer cell, it can bind BTK covalently, like a first- or second-generation drug; if it enters a cancer cell that has already acquired a C481 mutation, it can bind non-covalently, like a third-generation drug.” In other words, lobrutinib does not give one molecule two binding modes; rather, it allows the molecule to intelligently switch, under different cellular environments, to the binding mode best suited to the current target state, thereby achieving the effect of “comprehensive inhibition regardless of whether the cancer cell is mutant.” This is also where the core logic lies of its being called a covalent-and-non-covalent fourth-generation BTK inhibitor with a dual mechanism.
At the 2025 American Society of Hematology (ASH) Annual Meeting, Lupeng Pharmaceuticals updated data from the U.S. phase 1 clinical study (NCT04775745) of lobrutinib in patients with R/R chronic lymphocytic leukemia (R/R CLL) previously treated with BTK inhibitors. Between September 16, 2021 and March 28, 2025, the study enrolled 42 BTKi-treated R/R CLL patients, with a median of 4 prior lines of therapy (range 2–9 lines), of whom 21.4% had been treated with both covalent and non-covalent BTK inhibitors. As a comparator, in the third-generation BTK inhibitor pirtobrutinib’s pivotal phase 3 BRUIN CLL-321 study (NCT04666038), the median number of prior lines of therapy was only 3, and patients previously treated with non-covalent BTK inhibitors were excluded. Under heavier baseline conditions of the enrolled patients, lobrutinib still demonstrated encouraging efficacy: as of March 28, 2025, of 40 patients with evaluable response data, at dose levels ≥200 mg/day, the objective response rate (ORR) reached 78.3%, with an estimated median progression-free survival (mPFS) of 28.1 months; in 17 patients previously treated with both a BTK inhibitor and a Bcl-2 inhibitor (venetoclax), the ORR at the same dose level was 80.0% (8/10). All 42 BTKi-treated CLL patients underwent safety assessment; the majority of adverse events (AEs) were low-grade.
The confidence behind “head-to-head”: from phase 1 conviction to a global phase 3 gamble on more than 300 patients
In 2026, Lupeng Pharmaceuticals launched ROCKET-CLL (NCT07342478), a global phase 3 head-to-head trial of lobrutinib versus pirtobrutinib in patients with R/R chronic lymphocytic leukemia / small lymphocytic lymphoma (R/R CLL/SLL). The trial plans to enroll more than 300 patients who have previously been treated with a covalent BTK inhibitor (cBTKi) globally, randomized 1:1 to once-daily oral lobrutinib 200 mg or pirtobrutinib 200 mg. The primary endpoint is progression-free survival (PFS) as assessed by an Independent Review Committee (IRC); key secondary endpoints include overall survival (OS), among others. The first patient was enrolled in May 2026.
In Dr. Chen’s view, directly going head-to-head against an approved third-generation non-covalent BTK inhibitor requires considerable confidence, and this confidence stems from the ambition at the very start of the project: “We hoped that, by developing the innovative covalent-and-non-covalent mechanism, we could comprehensively surpass and replace previous-generation BTK inhibitors, so from the very start of project initiation we had already set the head-to-head research strategy.” Dr. Chen said: “The excellent efficacy and safety features shown in the phase 1 study reinforced our determination to advance the global phase 3 clinical trial.”
When asked at what stage a Chinese biotech has the confidence to launch more head-to-head studies, Dr. Chen gave three core elements: first, solid early-phase clinical research data — this is the foundation for daring to benchmark against a competitor; second, the need for breakthrough mechanism innovation — otherwise, even if you do a head-to-head, it is hard to establish an efficacy advantage; third, robust financial backing — phase 3 head-to-head studies require huge investment, and cannot succeed without investors’ long-term trust and support. Dr. Chen emphasized: “With the dual support of funding and technology, we were able to make the head-to-head study a practical core strategy.”
From monotherapy to combinations: pipeline synergy and the next step in patient benefit
Lobrutinib solves the resistance problem of BTK inhibitors, but Dr. Chen is well aware that monotherapy still has objective limitations. “In oncology, monotherapy usually has a ceiling, so combination therapy is a very critical strategy.” At present, Lupeng’s core pipeline includes, in addition to lobrutinib (LP-168), the Bcl-2 inhibitor letoclax (LP-108) and a Bcl-2/Bcl-xL dual-target inhibitor (LP-118). These three drugs form the company’s “internal combination punches” in the combination strategy. On the basis of lobrutinib, the company can combine LP-108 or LP-118, and is also actively exploring its synergy potential with chemotherapy, monoclonal antibodies, bispecific antibodies, ADCs and even CAR-T.
Letoclax is positioned as a Bcl-2 inhibitor with higher selectivity and oral bioavailability, directly benchmarked against the approved and clinically well-validated venetoclax. LP-118, as a Bcl-2/Bcl-xL dual-target inhibitor, simultaneously inhibits Bcl-2 and Bcl-xL, blocking the compensatory survival pathway of cancer cells, and extends the therapeutic window to cancer types that depend primarily on Bcl-xL — such as some solid tumors with acquired resistance to selective Bcl-2 inhibitors, acute lymphoblastic leukemia (ALL), and others.
However, the Bcl-xL target is a double-edged sword. Although Bcl-xL also has anti-tumor activity, it is critical for platelet survival. This on-target toxicity of “hitting the target inevitably causes collateral damage” means that once the inhibition intensity exceeds the safety threshold, severe thrombocytopenia and even bleeding risk may result. Dr. Chen revealed that LP-118 was designed around a key hypothesis: Bcl-xL inhibitory activity must be carefully titrated — neither too strong nor too weak — and only by finding this “middle ground” can anti-tumor activity be retained while keeping platelet toxicity within an acceptable range. Based on this thinking, LP-118 is considered to carry three notable advantages: first, prominent activity in Bcl-2-selective cells; second, ability to inhibit resistance mutations such as G101V; and third — and most importantly — precisely tuning Bcl-xL activity through differentiated design, achieving the aforementioned “balance of strong and weak.”
Conclusion
From the mechanism breakthrough of “covalent and non-covalent,” to the strategic choice of “whether to do a head-to-head,” to the molecular-design problem of “how to balance efficacy and toxicity,” the answers given by Dr. Chen and the Lupeng team collectively point to a distinctive methodology: not content with linear iteration along existing technological paths, but seeking, among options that appear mutually exclusive, an optimal solution that has the best of both. As ROCKET-CLL and other global phase 3 studies continue to advance, whether this “inclusive” logic can deliver on clinical value in a broader patient population will not only set a new benchmark for fourth-generation BTK inhibitors, but will also provide a key footnote for the global breakout of Chinese biotechs.